Osaic Holdings’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.95K Hold
356
– – ﹤0.01% 6691
2026
Q2
$9.14K Buy
+356
New +$8.76K ﹤0.01% 6655

Other funds holding THNR

Osaic Holdings's THNR Position: Q3 2026 in Review

Osaic Holdings held its Amplify Weight Loss Drug & Treatment ETF (THNR) position steady in Q3 2026 at 356 shares worth $8.95K. The position accounts for ﹤0.01% of the portfolio, ranked #6691.

Osaic Holdings first reported a position in THNR in Q2 2026 and has held it in 2 quarters since. The position peaked at $9.14K in Q2 2026. 6 funds tracked by Wall St. Rank hold THNR as of Q3 2026.

  • Osaic Holdings held 356 shares of Amplify Weight Loss Drug & Treatment ETF worth $8.95K as of Q3 2026.
  • Osaic Holdings left its Amplify Weight Loss Drug & Treatment ETF share count unchanged in Q3 2026.
  • Amplify Weight Loss Drug & Treatment ETF made up ﹤0.01% of Osaic Holdings's portfolio in Q3 2026, its #6691 holding.
  • Osaic Holdings first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q2 2026 and has held it in 2 quarters since.
  • Osaic Holdings's Amplify Weight Loss Drug & Treatment ETF position peaked at $9.14K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q3 2026.

Based on Osaic Holdings's 13F filing for Q3 2026, filed 12 Nov 2026.